Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- RSI is at a high level of 74. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum IRVINE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it ha...
IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 23rd Annual Needham Virtual Growth Conference. Presentation details: Date: January 15, 2021 Time: 10:45am ESTInvestors can register for the conference here: https://wsw.com/webcast/needham103/ocx/Follow...
Investors need to pay close attention to OncoCyte (OCX) stock based on the movements in the options market lately.
The cancer detection company said it has licensed a lung cancer test to China's Burning Rock Biotech.
In Q3, OncoCyte Corporation Common Stock (AMEX: OCX) posted sales of $555.00 thousand. Earnings were up 5.2%, but OncoCyte Corporation Common Stock still reported an overall loss of $9.22 million. OncoCyte Corporation Common Stock collected $143.00 thousand in revenue during Q2, but reported earnings showed a $8.77 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts i...
Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd. to bring OncoCyte's DetermaRX test for early-stage lung cancer patients to China. Trading volume spiked to 8.3 million shares, compared with the full-day average of about 419,500 shares. "This agreement with Burning Rock accelerates the ongoing expansi...
IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference. Presentation details: Date: Tuesday, December 15, 2020 Time: 12:40 – 1:00PM ESTInvestors can register for the conference HERE. Following the conference...
Aligns Oncocyte with one of China’s fastest growing NGS-based cancer therapy selection companies; China is considered to be the world’s largest early-stage lung cancer market Exclusive agreement includes payments of up to $6M in the first year and ongoing per test feesIRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum...
GUANGZHOU, China, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx™, a risk stratification test for early stage lung cancer patients, to China. Even though early-stage non-small-cell lung cancer (NSCLC) generally demonstrates a good prognosis after surgery, a significant proportion of early-stage NSCL...